Article Versions Notes

Chen C-C, Hsu C-C, Chen S-L, Lin P-H, Chen J-P, Pan Y-R, Huang C-E, Chen Y-J, Chen Y-Y, Wu Y-Y, et al. RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3. Cancers. 2021; 13(19):5024. https://doi.org/10.3390/cancers13195024

Chen, Chih-Cheng, Chia-Chen Hsu, Sung-Lin Chen, Po-Han Lin, Ju-Pei Chen, Yi-Ru Pan, Cih-En Huang, Ying-Ju Chen, Yi-Yang Chen, Yu-Ying Wu, and et al. 2021. "RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3" Cancers 13, no. 19: 5024. https://doi.org/10.3390/cancers13195024

Chen, C.-C., Hsu, C.-C., Chen, S.-L., Lin, P.-H., Chen, J.-P., Pan, Y.-R., Huang, C.-E., Chen, Y.-J., Chen, Y.-Y., Wu, Y.-Y., & Yang, M.-H. (2021). RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3. Cancers, 13(19), 5024. https://doi.org/10.3390/cancers13195024